Peter R. Bernstein, Ph.D.
Founder and Principal at PhaRmaB LLC
Peter R. Bernstein, Ph.D. is the founder and Principal at PhaRmaB LLC, a consulting firm dedicated to the discovery and development of new, safe and effective pharmaceuticals. Peter also holds multiple editorial and academic appointments. Most notably, he is the BMCL Digests Editor for Bioorganic & Medicinal Chemistry Letters, Section Editor for Annual Reports in Medicinal Chemistry, and is an Adjunct Professor of Chemistry & Biochemistry at the University of Delaware. Prior to this, Peter held research and management positions of increasing responsibility at ICI / Zeneca / AstraZeneca Pharmaceuticals during a professional career that covered several disease areas. Over the course of his tenure, the teams he was on submitted more than ten compounds for clinical development. One of these, Accolate, was the first new MOA for the treatment of Asthma approved by the FDA in over twenty-five years. In his last position, Senior Principal Scientist AZ CNS Pain Research Area he led multiple project teams and work groups focused on psychiatry and cognitive disorders. Peter was a postdoctoral fellow at the University of Wisconsin, Madison and received his Ph.D. in 1977 from Columbia University with Gilbert Stork in organic chemistry. Following his retirement from AstraZeneca in 2010, he was named Distinguished Lecturer for the AstraZeneca Excellence in Chemistry Award. Also, in 2011 he was named to the ACS Division of Medicinal Chemistry Hall of Fame.